Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer: results from two randomized studies

Objectives: Clinical benefits of immune-checkpoint blockade (ICB) versus standard chemotherapy have been established in unselected non-small cell lung cancer (NSCLC). However, the response to ICB therapy among patients is heterogeneous in clinical practice. Materials and Methods: We retrospectively...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Si-Cong, Tang, Xin-Ran, Long, Li-Li, Bai, Xue, Zhou, Jian-Guo, Duan, Zhi-Jiao, Wang, Jian, Fu, Qiang John, Zhu, Hong-Bo, Guo, Xue-Jun, Zhang, Yan-Pei, Guo, Ze-Qin, Wu, De-Hua, Dong, Zhong-Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078693/
https://www.ncbi.nlm.nih.gov/pubmed/33996262
http://dx.doi.org/10.1080/2162402X.2021.1909296

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078693/
https://www.ncbi.nlm.nih.gov/pubmed/33996262
http://dx.doi.org/10.1080/2162402X.2021.1909296

Ejemplares similares